Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxinshutong capsule for chronic heart failure with reduced ejection fraction caused by coronary heart disease
ChiCTR1900023877Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Zhejiang Chinese Medicine University
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Guanxin Shutong Capsule in coronary arteriosclerosis and heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by The Second Affiliated Hospital of Zhejiang Chinese Medicine University. Primary endpoint: 6-minute walking distance improvement. Planned start Aug 2018; status: not yet recruiting.
02
Drugs
Guanxin Shutong Capsule
03
Conditions
coronary arteriosclerosisheart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on ChiCTR1900023877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023877.